The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: A phase II study

Carlo Carnaghi, Armando Santoro, Lorenza Rimassa, Roberto Doci, Riccardo Rosati, Vittorio Pedicini, Giuseppe Gullo, Monica Zuradelli, Giovanni Abbadessa, Emanuela Morenghi, Ilaria Marcon, Isabella Garassino

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Intra-arterial chemotherapy in patients with liver metastases from colorectal cancer has some limitations such as hepatic toxicity and extra-hepatic progression. With the aim of overcoming these limitations, a phase II trial was designed to assess the efficacy and tolerability of a hybrid chemotherapy regimen with systemic infusion of oxaliplatin and folinic acid associated with intra-arterial 5-fluorouracil. Thirty-nine patients with colorectal liver metastases were recruited. The median age was 59 years, 30 patients (77%) had synchronous metastases, and half of the patients were chemo-naive. A total of 313 chemotherapy cycles were administered (median number 8). Treatment was well tolerated and hepatic toxicity negligible. Out of 34 evaluable patients an ORR of 41%. was observed. Eight patients (21%) underwent radical liver surgery. The median time to progression (TTP) was 10 months (range 2-63) and the median overall survival (OS) 21 months (range 6-63). Extra-hepatic progression was observed in six patients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached.

Original languageEnglish
Pages (from-to)479-485
Number of pages7
JournalInvestigational New Drugs
Volume25
Issue number5
DOIs
Publication statusPublished - Oct 2007

Fingerprint

oxaliplatin
Leucovorin
Fluorouracil
Neoplasm Metastasis
Drug Therapy
Liver

Keywords

  • 5-fluorouracil
  • Chemotherapy
  • Colorectal
  • Intra-arterial
  • Intra-hepatic
  • Liver
  • Metastases
  • Oxaliplatin

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

@article{0b112e7cdeb5421788c1f36c91d4b3e2,
title = "The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: A phase II study",
abstract = "Intra-arterial chemotherapy in patients with liver metastases from colorectal cancer has some limitations such as hepatic toxicity and extra-hepatic progression. With the aim of overcoming these limitations, a phase II trial was designed to assess the efficacy and tolerability of a hybrid chemotherapy regimen with systemic infusion of oxaliplatin and folinic acid associated with intra-arterial 5-fluorouracil. Thirty-nine patients with colorectal liver metastases were recruited. The median age was 59 years, 30 patients (77{\%}) had synchronous metastases, and half of the patients were chemo-naive. A total of 313 chemotherapy cycles were administered (median number 8). Treatment was well tolerated and hepatic toxicity negligible. Out of 34 evaluable patients an ORR of 41{\%}. was observed. Eight patients (21{\%}) underwent radical liver surgery. The median time to progression (TTP) was 10 months (range 2-63) and the median overall survival (OS) 21 months (range 6-63). Extra-hepatic progression was observed in six patients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached.",
keywords = "5-fluorouracil, Chemotherapy, Colorectal, Intra-arterial, Intra-hepatic, Liver, Metastases, Oxaliplatin",
author = "Carlo Carnaghi and Armando Santoro and Lorenza Rimassa and Roberto Doci and Riccardo Rosati and Vittorio Pedicini and Giuseppe Gullo and Monica Zuradelli and Giovanni Abbadessa and Emanuela Morenghi and Ilaria Marcon and Isabella Garassino",
year = "2007",
month = "10",
doi = "10.1007/s10637-007-9048-5",
language = "English",
volume = "25",
pages = "479--485",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "5",

}

TY - JOUR

T1 - The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases

T2 - A phase II study

AU - Carnaghi, Carlo

AU - Santoro, Armando

AU - Rimassa, Lorenza

AU - Doci, Roberto

AU - Rosati, Riccardo

AU - Pedicini, Vittorio

AU - Gullo, Giuseppe

AU - Zuradelli, Monica

AU - Abbadessa, Giovanni

AU - Morenghi, Emanuela

AU - Marcon, Ilaria

AU - Garassino, Isabella

PY - 2007/10

Y1 - 2007/10

N2 - Intra-arterial chemotherapy in patients with liver metastases from colorectal cancer has some limitations such as hepatic toxicity and extra-hepatic progression. With the aim of overcoming these limitations, a phase II trial was designed to assess the efficacy and tolerability of a hybrid chemotherapy regimen with systemic infusion of oxaliplatin and folinic acid associated with intra-arterial 5-fluorouracil. Thirty-nine patients with colorectal liver metastases were recruited. The median age was 59 years, 30 patients (77%) had synchronous metastases, and half of the patients were chemo-naive. A total of 313 chemotherapy cycles were administered (median number 8). Treatment was well tolerated and hepatic toxicity negligible. Out of 34 evaluable patients an ORR of 41%. was observed. Eight patients (21%) underwent radical liver surgery. The median time to progression (TTP) was 10 months (range 2-63) and the median overall survival (OS) 21 months (range 6-63). Extra-hepatic progression was observed in six patients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached.

AB - Intra-arterial chemotherapy in patients with liver metastases from colorectal cancer has some limitations such as hepatic toxicity and extra-hepatic progression. With the aim of overcoming these limitations, a phase II trial was designed to assess the efficacy and tolerability of a hybrid chemotherapy regimen with systemic infusion of oxaliplatin and folinic acid associated with intra-arterial 5-fluorouracil. Thirty-nine patients with colorectal liver metastases were recruited. The median age was 59 years, 30 patients (77%) had synchronous metastases, and half of the patients were chemo-naive. A total of 313 chemotherapy cycles were administered (median number 8). Treatment was well tolerated and hepatic toxicity negligible. Out of 34 evaluable patients an ORR of 41%. was observed. Eight patients (21%) underwent radical liver surgery. The median time to progression (TTP) was 10 months (range 2-63) and the median overall survival (OS) 21 months (range 6-63). Extra-hepatic progression was observed in six patients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached.

KW - 5-fluorouracil

KW - Chemotherapy

KW - Colorectal

KW - Intra-arterial

KW - Intra-hepatic

KW - Liver

KW - Metastases

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=34547663856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547663856&partnerID=8YFLogxK

U2 - 10.1007/s10637-007-9048-5

DO - 10.1007/s10637-007-9048-5

M3 - Article

C2 - 17492399

AN - SCOPUS:34547663856

VL - 25

SP - 479

EP - 485

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 5

ER -